Drug Discovery & Optimization

JPT applies its proprietary peptide technologies, bioinformatic and medicinal chemistry know-how in the following areas:

Our experience in drug discovery and optimization can be applied in peptide based drug and vaccine projects, in the discovery of peptidic additives for the cosmetic and nutritional industry, in the development of affinity ligands for the purification of biomolecules, as well as in content determination for novel immune diagnostics.

Here are some example applications:

Target identification and validation
High-throughput screening
Binding affinity and specificty
Structure-activity relationship (SAR) studies:
Immunotherapy development:
Peptides in drug delivery systems

Applications

Discovery of peptidic agonistic or antagonistic ligands for proteins, protein complexes or antibodies
Optimization of peptides in terms of binding affinity, agonistic or antagonistic efficacy and physicochemical and PK properties
Identification and optimization of affinity ligands for the purification of therapeutic proteins or antibodies
Identification and optimization for the development of alternative binding assays for complicated target proteins (e.g. membrane proteins)
Development of peptides as active ingredients or excipients in drug formulations (e.g. to increase stability) or nutritional and cosmetic products, respectively

References

Octaarginine Improves the Efficacy of Nitazoxanide against Cryptosporidium parvum
Nguyen-Ho-Bao et al., Pathogens (2022) - PMID: 35745507
Immundiagnostische Mittel und Verfahren für den Nachweis und die Differenzierung von Coronavirus-Infektionen, Patent application DE No. 10 2020 125 915.8 (2020)
Detection of Neurogenerative Diseases
Moussaoui et al, Patent WO 2017/153922 (2017)
Peptide Mimotopes of the CD3 T-Cell Co-Receptor Epsilon Chain and uses thereof
Schnatbaum et al, Patent WO 2017/008844 (2015)
Peptide Mimotopes of Claudin 18.2 and uses thereof
Schnatbaum et al, Patent WO 2015/113576 (2014)
Peptide Microarrays Enable Rapid Mimotope Optimization for Pharmacokinetic Analysis of the Novel Therapeutic Antibody IMAB362
Schnatbaum et al., Biotechnol J. (2014) - PMID: 24497417